文献速递神经核医学核素与放射性配体治疗

单次静脉给予奥曲肽后小肠神经内分泌肿瘤及正常组织的受体耗竭与恢复:68Ga-DOTATOC PET/CT 评估

Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by 68Ga-DOTATOC PET/CT.
PubMed 文献 · EJNMMI Res · 2021-11-25

本研究对 12 例小肠神经内分泌肿瘤患者单次静脉给予 400 µg 短效奥曲肽后,用 68Ga-DOTATOC PET/CT 动态观察肿瘤与正常器官的受体摄取随时间变化。结果显示肿瘤 SUV 在注射后 1 小时较基线显著下降,随后回升,至 4 小时和 7 小时与基线相近;而肝、脾、胰腺摄取至 7 小时仍显著低于基线。作者认为肿瘤生长抑素受体再循环快于正常组织,这为 PRRT 前给予冷肽保护正常组织提供了可能。

要点

  • 单次静脉 400 µg 奥曲肽后,肿瘤 SUV 于 1 小时较基线显著下降,4 小时和 7 小时回升至与基线相近。
  • 肝、脾、胰腺摄取至 7 小时仍显著低于基线,肿瘤受体再循环快于正常组织。
  • 肿瘤 Ki 随时间显著升高,且与 SUV 及肿瘤/血比值呈线性相关。

核心结论

  • 小肠神经内分泌肿瘤的生长抑素受体再循环快于肝、脾和胰腺。
  • 作者认为这为 PRRT 前数小时给予单次冷肽以保护正常组织提供了可能,并可能额外改善治疗药物在肿瘤中的可及性与摄取。

研究设计与样本

  • 研究纳入 12 例小肠神经内分泌肿瘤患者,单次静脉给予 400 µg 奥曲肽。
  • 每次 PET/CT 开始时给予 68Ga-DOTATOC 167 ± 21 MBq、23.5 ± 4.2 µg(均值 ± 标准差,n = 12)。
  • 行腹部动态 68Ga-DOTATOC PET/CT 三个时段(0、3、6 小时)及全身静态 PET/CT(1、4、7 小时)。
  • 以既往临床全身 68Ga-DOTATOC 扫描作为基线,计算肿瘤 SUV 与净摄取率 Ki 及健康器官 SUV。

主要发现

  • 肿瘤 SUV 从基线至注射后 1 小时显著下降,随后随时间升高,至 4 小时和 7 小时与基线相近。
  • 肿瘤净摄取率 Ki 随时间显著升高,且与 SUV 和肿瘤/血比值均呈线性相关。
  • 肝、脾、胰腺摄取至 7 小时仍显著低于基线水平,肿瘤受体周转超过正常组织,肿瘤 68Ga-DOTATOC 摄取恢复主要在 7 小时完成。
  • 大肿瘤(≥ 4 mL)第 1 次与第 2 次 PET 间 Ki 和 SUV 显著升高,小肿瘤(> 1 至 < 4 mL)无显著变化。

临床怎么用

  • 作者认为可在 PRRT 前数小时给予单次冷肽以保护正常组织,并可能额外改善治疗药物在肿瘤中的可及性与摄取。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-grade neuroendocrine tumors (NETs) are characterized by an abundance of somatostatin receptors (SSTR) that can be targeted with somatostatin analogs (SSA). When activated with a single dose of SSA, the receptor-ligand complex is internalized, and the receptor is by default recycled within 24 h. Ongoing medication with long-acting SSAs at 68Ga-DOTA-SSA-PET has been shown to increase the tumor-to-normal organ contrast. This study was performed to investigate the time-dependent extended effect (7 h) of a single intravenous dose of 400 µg short-acting octreotide on the tumor versus normal tissue uptake of 68Ga-DOTATOC. METHODS: Patients with small-intestinal NETs received a single intravenous dose of 400 µg octreotide and underwent dynamic abdominal 68Ga-DOTATOC-PET/CT at three sessions (0, 3 and 6 h) plus static whole-body (WB) PET/CT (1, 4 and 7 h), starting each PET/CT session by administering 167 ± 21 MBq, 23.5 ± 4.2 µg (mean ± SD, n = 12) of 68Ga-DOTATOC. A previously acquired clinical whole-body 68Ga-DOTATOC scan was used as baseline. SUV and net uptake rate Ki were calculated in tumors, and SUV in healthy organs. RESULTS: Tumor SUV decreased significantly from baseline to 1 h post-injection but subsequently increased over time and became similar to baseline at 4 h and 7 h. The tumor net uptake rate, Ki, similarly increased significantly over time and showed a linear correlation both with SUV and tumor-to-blood ratio. By contrast, the uptake in liver, spleen and pancreas remained significantly below baseline levels also at 7 h and the receptor turn-over in tumors thus exceeded that in the normal tissue, with restitution of tumor 68Ga-DOTATOC uptake mainly completed at 7 h. These results however differed depending on tumor size, with significant increases in Ki and SUV between the 1st and 2nd PET, in large tumors (≥ 4 mL) but not in small (> 1 to < 4 mL) tumors. CONCLUSION: SSTR recycling is faster in small-intestinal NETs than in liver, spleen and pancreas. This opens the possibility to protect normal tissues during PRRT by administering a single dose of cold peptide hours before peptide receptor radionuclide therapy (PRRT), and most likely additionally improve the availability and uptake of the therapeutic preparation in the tumors.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Jahn U, Ilan E, Velikyan I, et al. Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by 68Ga-DOTATOC PET/CT. EJNMMI Res. 2021. PMID: 34822040. doi:10.1186/s13550-021-00860-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。